Related Experiment Video
Updated: Aug 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their
D M van Reyk1, S Sarel, N H Hunt
1Department of Pathology, University of Sydney, New South Wales, Australia.
Abstract:
The effects of three iron chelators (ADR-529/ICRF-187; omadine/pyrithione; and a newly synthesized pyridoxal-based iron chelator, SAG-15) on cultured BALB/c murine lymph node cells stimulated with phorbol myristate acetate and ionomycin have been investigated. All three agents were found to inhibit [3H]-thymidine incorporation after 66-72 h incubation. Pretreatment of ADR-529 and omadine with Fe(III) or Fe(II) ions did not prevent their inhibitory effects. However, pretreatment of SAG-15 with Fe(II) or Fe(III) ions led to a significant increase in the ID50. Time-course studies of cell viability and thymidine incorporation demonstrated that the inhibitory effect of omadine was attributable to cell killing while for ADR-529 and SAG-15 there were both cytostatic and cytotoxic effects. Cell cycle analysis showed that treatment of cells with ADR-529 led to arrest in G2/M while treatment with SAG-15 led to a G0/G1 arrest. Iron has an obligatory role in T-lymphocyte activation that may be related to the formation of reactive oxygen species. SAG-15 is a new iron chelator that will help in the elucidation of the precise role of iron in lymphoproliferation. Since SAG-15 is an extremely effective iron chelator in vivo it has potential as an immunosuppressive agent.

